DNLI
Price
$15.96
Change
+$0.08 (+0.50%)
Updated
Oct 24 closing price
Capitalization
2.33B
3 days until earnings call
Intraday Buy/Sell Signals
KROS
Price
$15.04
Change
+$0.16 (+1.08%)
Updated
Oct 24 closing price
Capitalization
458.21M
3 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

DNLI vs KROS

Header iconDNLI vs KROS Comparison
Open Charts DNLI vs KROSBanner chart's image
Denali Therapeutics
Price$15.96
Change+$0.08 (+0.50%)
Volume$1.07M
Capitalization2.33B
Keros Therapeutics
Price$15.04
Change+$0.16 (+1.08%)
Volume$703.28K
Capitalization458.21M
DNLI vs KROS Comparison Chart in %
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. KROS commentary
Oct 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 27, 2025
Stock price -- (DNLI: $15.96 vs. KROS: $15.04)
Brand notoriety: DNLI and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 53% vs. KROS: 106%
Market capitalization -- DNLI: $2.33B vs. KROS: $458.21M
DNLI [@Biotechnology] is valued at $2.33B. KROS’s [@Biotechnology] market capitalization is $458.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while KROS’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • KROS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both DNLI and KROS are a good buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а -4.20% price change this week, while KROS (@Biotechnology) price change was +8.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

KROS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.33B) has a higher market cap than KROS($458M). KROS YTD gains are higher at: -4.991 vs. DNLI (-21.688). KROS has higher annual earnings (EBITDA): 25.5M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. KROS (690M). KROS has less debt than DNLI: KROS (18M) vs DNLI (46.6M). KROS has higher revenues than DNLI: KROS (233M) vs DNLI (0).
DNLIKROSDNLI / KROS
Capitalization2.33B458M510%
EBITDA-521.52M25.5M-2,045%
Gain YTD-21.688-4.991435%
P/E RatioN/A47.00-
Revenue0233M-
Total Cash899M690M130%
Total Debt46.6M18M259%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
90
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIKROS
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 13 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSQTX36.680.38
+1.05%
Goldman Sachs Small Cap Value Inv
JAMEX38.680.38
+0.99%
Jamestown Equity
IJSTX14.080.11
+0.79%
VY® JPMorgan Small Cap Core Equity S2
CVSOX15.760.01
+0.06%
Calamos Market Neutral Income R6
ARGFX81.87-0.11
-0.13%
Ariel Fund Investor

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+1.08%
INO - KROS
53%
Loosely correlated
+3.56%
AXON - KROS
43%
Loosely correlated
+2.73%
RAPT - KROS
39%
Loosely correlated
-1.57%
DNLI - KROS
39%
Loosely correlated
+0.50%
ALT - KROS
39%
Loosely correlated
-0.25%
More